Russian Watchdog Says Novo Broke Competition Law

Law360, New York (September 24, 2010, 4:34 PM EDT) -- Russian competition authorities said Friday they planned to fine Novo Nordisk A/S, the largest insulin maker in the world, for allegedly limiting competition in the pharmaceutical market.

Russia’s Federal Antimonopoly Service accused the Danish company’s subsidiary of refusing to sign contracts with individual buyers and “creating discriminatory conditions for potential partners in comparison with established ones.”

The company failed to provide economic or technological justification for the restrictions, FAS said.

The actions violated Russia’s Law "On Protection of Competition," which prohibits actions or omissions by a...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.